Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Gerneth v. Chiasma, Inc. et al
Case Number:
1:16-cv-11082
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- A&O Shearman
- Block & Leviton
- Foley Hoag
- Goodwin Procter
- Hutchings Barsamian
- Johnson Fistel
- Meehan Boyle
- Pomerantz LLP
- Robbins Geller
- Ropes & Gray
Companies
Sectors & Industries:
-
August 22, 2019
Chiasma Investors Want Bond From 'Frivolous' Deal Objectors
Chiasma investors fought back Wednesday against a pair of objectors to the $18.7 million settlement of a shareholder suit against the biopharmaceutical company, arguing that they lack standing to appeal and should have to post an appeal bond.
-
June 28, 2019
2 Firms Score $5.6M For Work On $18.7M Chiasma Deal
A Boston federal court has awarded Robbins Geller Rudman & Dowd LLP and Johnson Fistel LLP over $5.6 million in attorney fees for their work securing an $18.7 million settlement in an investor class action alleging biopharmaceutical company Chiasma misrepresented a drug's chances for winning FDA approval.
-
March 01, 2019
Pharma Co. Chiasma To Settle Investors' IPO Suit For $18.7M
Biopharmaceutical company Chiasma and a proposed class of shareholders asked a Massachusetts judge for preliminary approval Friday of an $18.75 million settlement over claims the company misled prospective investors in its initial public offering about the chances of a new drug getting regulatory approval.
-
February 16, 2018
Pharma Co. Chiasma Can't Escape Investor Suit, Judge Rules
A Massachusetts federal judge on Thursday ruled that biopharmaceutical company Chiasma Inc. must face a proposed class action alleging investors in its 2015 initial public offering were misled about the prospects for regulatory approval of its product candidate Mycapssa, an oral treatment for a rare hormonal disorder known as acromegaly.